Talk with your doctor about prescribing the generic version going forward, since it will ultimately save money for you, your insurance, or both.
Essex (PRWEB UK) 11 June 2014
On May 17 2014, The Medicines and Healthcare Products Regulatory Agency (MHRA) approved of the generic version of the antidepressant Escitalopram. Previous application for generic version was rejected by the European Medicines Agency (EMA) in February 2010. EMA concluded then that there was insufficient evidence to show that the generic medicines had comparable effectiveness and safety as the reference medicine.
Cipralex is licensed for the treatment of adults and children over 12 years of age with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The Major Depressive Disorder (MDD) is the most common form of clinical depression and 13-17% of the population are affected. The symptoms include, sadness; loss of interest; feeling guilt ridden; irritable; a change in appetite.
The launch of generic Escitalopram marks the end of an era for branded selective serotonin reuptake inhibitor (SSRI) antidepressants.
When considering generic substitution, Escitalopram generic show a cost saving of £20.00GBP per calendar month when you buy from Asset Chemist.
Asset Chemist Pharmacist says, “Talk with your doctor about prescribing the generic version going forward, since it will ultimately save money for you, your insurance, or both.”
The patent expiry on May 17th 2014 in the UK and now Asset Chemist brings to you the first generic version of the antidepressant on June 10, 2014.
For further press information, please contact:
Asset Chemist Ltd
128 Dock Road, Tilbury, Essex
RM18 7BJ Tel: 01375 846316